Work

Leveraging managed access with life-cycle reassessment in Asia-Pacific: advancing the learning of health system matters for innovative medicines in oncology

Year: 2025

Type: article

Abstract: The acceleration of oncology drug research and development (R&D) and approvals over the past decade marks a watershed moment for patients and the pharmaceutical industry worldwide. Several uncertainties, often neglected, created by expedited approvals make it crucial to establish a learning health system that can leverage the initial reimbursement decisions to post-marketing lifecycle reassessment of the safety, effectiveness and cost-effectiveness of anti-cancer drugs, so-called lifecycle health technology assessment (HTA).

Source: The Lancet Regional Health - Western Pacific

DOI: 10.1016/j.lanwpc.2025.101769

Authors: Yuanshi Jiao, Zonglin Dai, Jiangnan Zhu, Manuel A. Espinoza, Xue Li

Institution: University of Hong Kong

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,250